Relypsa has reported that the Phase IIb trial studying the safety and efficacy of patiromer as a treatment for hyperkalemia has met its primary efficacy endpoint of significant mean change of serum potassium by week four. Additionally, treatment with patiromer maintained mean serum potassium within the normal range for up to one year, supporting persistence of the potassium lowering effect of patiromer over time. These clinically meaningful results provide supportive evidence for the efficacy, ...